oral semaglutide cardiovascular benefit Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Oral Semaglutide (Wegovy) for Weight

The cost is justified when fat loss is the primary goal and metabolic demand is high patients on GLP-1 protocols, post-bariatric surgery, or in aggressive caloric deficits see measurable differences in energy, recovery, and body composition that single-formulation use doesnt replicate

Heres the honest caveat: how much of the lab research shows up on your face depends on the formula, the concentration, and how consistently you use it

u/gersktay We were impressed by u/gersktay's story and realistic view on his life expectancy if he continued at the weight he was

Whatever you will actually use consistently is the right answer

A study from the University of Pennsylvania and Cedars-Sinai Medical Center found a 700% increase in use of the drugs for patients without diabetes from 2019 to 2023